Skip to main
PRPH
PRPH logo

ProPhase Labs (PRPH) Stock Forecast & Price Target

ProPhase Labs (PRPH) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ProPhase Labs Inc. is poised for significant financial growth, evidenced by its plan to increase lozenge production capacity by over 400% by December 2024, responding to robust market demand. The anticipated commercial launch of Equivir, coupled with positive preliminary clinical results, could significantly enhance the company’s top-line revenue, with forecasts suggesting Pharmaloz could generate $15 million in annualized revenue as early as 1Q24 and reach $30-$35 million by early 3Q24. Additionally, recent investments in automation are expected to boost production capacity substantially, which aligns with the company's 100% year-over-year growth in its non-Cold-EEZE contract manufacturing division.

Bears say

ProPhase Labs Inc. reported a total revenue of $8.4 million for the latest quarter, indicating a significant 65% year-over-year decline and falling short of the projected $12.3 million. The sharp decline in revenue was primarily attributed to an $18 million decrease in the diagnostic services segment, despite a slight offset from a $2.2 million increase in consumer products. The company faces several operational risks, including challenges in expanding manufacturing capacity, achieving market adoption for personal genomics products, and maintaining steady revenue streams from dietary supplements, which contribute to a negative outlook on its stock performance.

ProPhase Labs (PRPH) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ProPhase Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ProPhase Labs (PRPH) Forecast

Analysts have given ProPhase Labs (PRPH) a Strong Buy based on their latest research and market trends.

According to 1 analysts, ProPhase Labs (PRPH) has a Strong Buy consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ProPhase Labs (PRPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.